Leona Plum-Mörschel

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Bariatric Surgery

Placebo Controlled

Top Venues

Diabetes, obesity & metabolism

Journal of diabetes science and technology

This page only lists publications with an associated author ORCID identifier.

Publications

Consuelo Handy, Mohamed Sabih Chaudhry, Muhammad Rafaqat Ali Qureshi, Bradley Love, John Shillingford, Leona Plum-Mörschel, Eric Zijlstra
Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study. Journal of diabetes science and technology (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism (2022)